A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
BACKGROUND
Due to the inherent limitations of current generation BVSs, complex coronary artery disease often contains BVS unsuitable segments. Our aim was to assess the feasibility of a hybrid approach using bioresorbable vascular scaffolds (BVSs) and drug-eluting stents (DESs) for the treatment of complex coronary artery lesions not suitable for a scaffolding only approach.


METHODS
A retrospective multicenter cohort analysis was performed on patients with complex de novo or in-stent restenosis lesions treated with a hybrid BVS (Absorb BVS, Abbott Vascular, Santa Clara, CA) and DES strategy. The primary endpoint was target lesion failure (TLF) defined as a composite of cardiac death, target-vessel myocardial infarction (MI) and target lesion revascularization (TLR).


RESULTS
A total of 98 patients (105 lesions) were treated with the hybrid strategy. Isolated long lesions in which either proximal or distal reference vessel diameters were not suitable for BVS were an indication in 36.2% (n=38) of cases. In contrast, 28% (n=29) of lesions treated with the hybrid strategy were bifurcations in which the side branch was predominantly treated with DES (n=28). DES bailout after BVS implantation was an indication in 21.9% (n=23 lesions). The rates of type B2/C and long lesions (>28mm) were 95.2% and 74.3% respectively. The mean total BVS and DES lengths implanted were 37.5±24.1mm and 25.0±14.7mm respectively. The rate of TLF in the overall cohort of patients (median follow-up 405days [interquartile range 189-658]) was 11.4% at 1-year. This was primarily driven by TLR (9.5%), with rates of cardiac death and target vessel MI of 2.1% and 1.4% respectively. No cases of definite or probable BVS/DES thrombosis occurred.


CONCLUSIONS
In conclusion, the use of a hybrid BVS/DES strategy was feasible and associated with acceptable outcomes at 1-year, considering the length and complexity of lesions treated. Further, larger studies with longer follow-up are needed to confirm our findings.
San Raffaele Hospital, Milan, Italy; EMO GVM Columbus, Milan, Italy.
Richard J
RJ
Jabbour
Bolognini Hospital Seriate, ASST Bergamo Est, Seriate (BG), Italy.
Alfonso
A
Ielasi
San Raffaele Hospital, Milan, Italy; EMO GVM Columbus, Milan, Italy.
Akihito
A
Tanaka
Borea Civil Hospital, Sanremo (IM), Italy.
Massimo
M
Leoncini
Fatebenefratelli Hospital, Milan, Italy.
Bernado
B
Cortese
Bolognini Hospital Seriate, ASST Bergamo Est, Seriate (BG), Italy.
Giulietta
G
Grigis
San Raffaele Hospital, Milan, Italy; EMO GVM Columbus, Milan, Italy.
Satoru
S
Mitomo
San Raffaele Hospital, Milan, Italy; EMO GVM Columbus, Milan, Italy.
Damiano
D
Regazzoli
Fatebenefratelli Hospital, Milan, Italy.
Gaetano
G
Di Palma
Borea Civil Hospital, Sanremo (IM), Italy.
Claudio
C
Rapetto
Bolognini Hospital Seriate, ASST Bergamo Est, Seriate (BG), Italy.
Maurizio
M
Tespili
San Raffaele Hospital, Milan, Italy; EMO GVM Columbus, Milan, Italy.
Antonio
A
Colombo
San Raffaele Hospital, Milan, Italy; EMO GVM Columbus, Milan, Italy. Electronic address: info@emocolumbus.it.
Azeem
A
Latib
D020341:Absorbable Implants / Q000009:adverse effects; D000368:Aged; D003324:Coronary Artery Disease / Q000628:therapy*; D003331:Coronary Vessels / Q000601:surgery*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000379:methods; D011474:Prosthesis Design; D012189:Retrospective Studies; D016896:Treatment Outcome
D000068338:Everolimus
Bioresorbable scaffold; Drug-eluting stent; Hybrid; Percutaneous coronary intervention